美国哈佛医学院Dan H. Barouch小组近期发现一种α4β7抗体对于SIVmac251病毒感染的恒河猴缺乏治疗效果。相关论文2019年9月6日发表在《科学》上。

据悉，停止抗逆转录病毒治疗（ART）后，对1型人类免疫缺陷病毒（HIV-1）感染的持续病毒控制，是HIV-1治愈领域的主要目标。最近的一项研究报道，在100％感染了含有nef基因终止密码子的减毒猴免疫缺陷病毒（SIV）的恒河猴中，施用针对α4β7的抗体能够产生持久的病毒控制。

研究人员在感染野生型致病性SIVmac251病毒的50只恒河猴中进行了类似的研究。在急性或慢性感染期间开始抗病毒治疗的动物中，抗-α4β7抗体注射对于病毒储库或ART停止后的病毒反弹没有可检测的影响。这些数据表明抗-α4β7抗体施用在恒河猴的致病性SIVmac251感染模型中，不提供治疗功效。

附：英文原文

Title: Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques

Author: Peter Abbink, Noe B. Mercado, Joseph P. Nkolola, Rebecca L. Peterson, Hubert Tuyishime, Katherine McMahan, Edward T. Moseley, Erica N. Borducchi, Abishek Chandrashekar, Esther A. Bondzie, Arshi Agarwal, Aaron J. Belli, Keith A. Reimann, Brandon F. Keele, Romas Geleziunas, Mark G. Lewis, Dan H. Barouch

Issue&Volume:Volume 365 Issue 6457

Abstract: Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent study reported that administration of an antibody against α4β7 induced durable virologic control after ART discontinuation in 100% of rhesus macaques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop codon in nef. We performed similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In animals that initiated ART during either acute or chronic infection, anti-α4β7 antibody infusion had no detectable effect on the viral reservoir or viral rebound after ART discontinuation. These data demonstrate that anti-α4β7 antibody administration did not provide therapeutic efficacy in the model of pathogenic SIVmac251 infection of rhesus macaques.

DOI: 10.1126/science.aaw8562

Source:https://science.sciencemag.org/content/365/6457/1029